Protocol Ledger

NCT06378138 · Phase II/III · RECRUITING

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Interventional Phase II/III clinical trial protocol NCT06378138 sponsored by Beijing InnoCare Pharma Tech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-15 Enrollment: 226 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06378138
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)226 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06378138
Protocol FieldVerified Registry Value
NCT IdentifierNCT06378138
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment226 participants (ESTIMATED)
Registered Start Date2024-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI